177 related articles for article (PubMed ID: 32286579)
1. Targeting STAT3 anti-apoptosis pathways with organic and hybrid organic-inorganic inhibitors.
Minus MB; Wang H; Munoz JO; Stevens AM; Mangubat-Medina AE; Krueger MJ; Liu W; Kasembeli MM; Cooper JC; Kolosov MI; Tweardy DJ; Redell MS; Ball ZT
Org Biomol Chem; 2020 May; 18(17):3288-3296. PubMed ID: 32286579
[TBL] [Abstract][Full Text] [Related]
2. Rhodium(II) Proximity-Labeling Identifies a Novel Target Site on STAT3 for Inhibitors with Potent Anti-Leukemia Activity.
Minus MB; Liu W; Vohidov F; Kasembeli MM; Long X; Krueger MJ; Stevens A; Kolosov MI; Tweardy DJ; Sison EA; Redell MS; Ball ZT
Angew Chem Int Ed Engl; 2015 Oct; 54(44):13085-9. PubMed ID: 26480340
[TBL] [Abstract][Full Text] [Related]
3. Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)-Resistant CML Lines While Circumventing Pharmacokinetic Liabilities.
Ali AM; Gómez-Biagi RF; Rosa DA; Lai PS; Heaton WL; Park JS; Eiring AM; Vellore NA; de Araujo ED; Ball DP; Shouksmith AE; Patel AB; Deininger MW; O'Hare T; Gunning PT
ChemMedChem; 2016 Apr; 11(8):850-61. PubMed ID: 27028877
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf.
Chen KF; Tai WT; Huang JW; Hsu CY; Chen WL; Cheng AL; Chen PJ; Shiau CW
Eur J Med Chem; 2011 Jul; 46(7):2845-51. PubMed ID: 21531053
[TBL] [Abstract][Full Text] [Related]
5. Discovery of new benzensulfonamide derivatives as tripedal STAT3 inhibitors.
Guo J; Yu W; Cai G; Zhang W; Li S; Zhu J; Song D; Kong L
Eur J Med Chem; 2018 May; 151():752-764. PubMed ID: 29674294
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib induces apoptosis in HL60 cells by inhibiting Src kinase-mediated STAT3 phosphorylation.
Zhao W; Zhang T; Qu B; Wu X; Zhu X; Meng F; Gu Y; Shu Y; Shen Y; Sun Y; Xu Q
Anticancer Drugs; 2011 Jan; 22(1):79-88. PubMed ID: 20881478
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel STAT3 small molecule inhibitors via in silico site-directed fragment-based drug design.
Yu W; Xiao H; Lin J; Li C
J Med Chem; 2013 Jun; 56(11):4402-12. PubMed ID: 23651330
[TBL] [Abstract][Full Text] [Related]
8. Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia.
Eiring AM; Page BDG; Kraft IL; Mason CC; Vellore NA; Resetca D; Zabriskie MS; Zhang TY; Khorashad JS; Engar AJ; Reynolds KR; Anderson DJ; Senina A; Pomicter AD; Arpin CC; Ahmad S; Heaton WL; Tantravahi SK; Todic A; Moriggl R; Wilson DJ; Baron R; O'Hare T; Gunning PT; Deininger MW
Leukemia; 2015 Mar; 29(3):586-597. PubMed ID: 25134459
[TBL] [Abstract][Full Text] [Related]
9. Curcumin Combined with Thalidomide Reduces Expression of
Mohammadi Kian M; Salemi M; Bahadoran M; Haghi A; Dashti N; Mohammadi S; Rostami S; Chahardouli B; Babakhani D; Nikbakht M
Drug Des Devel Ther; 2020; 14():185-194. PubMed ID: 32021103
[TBL] [Abstract][Full Text] [Related]
10. New naphthalene derivatives induce human lung cancer A549 cell apoptosis via ROS-mediated MAPKs, Akt, and STAT3 signaling pathways.
Xu WT; Shen GN; Luo YH; Piao XJ; Wang JR; Wang H; Zhang Y; Li JQ; Feng YC; Zhang Y; Zhang T; Wang SN; Wang CY; Jin CH
Chem Biol Interact; 2019 May; 304():148-157. PubMed ID: 30871965
[TBL] [Abstract][Full Text] [Related]
11. Proteomic identification of the oncoprotein STAT3 as a target of a novel Skp1 inhibitor.
Cheng X; Liu YQ; Wang GZ; Yang LN; Lu YZ; Li XC; Zhou B; Qu LW; Wang XL; Cheng YX; Liu J; Tao SC; Zhou GB
Oncotarget; 2017 Jan; 8(2):2681-2693. PubMed ID: 27835873
[TBL] [Abstract][Full Text] [Related]
12. Rational Design and Development of Novel CDK9 Inhibitors for the Treatment of Acute Myeloid Leukemia.
Han X; Song N; Saidahmatov A; Wang P; Wang Y; Hu X; Kan W; Zhu W; Gao L; Zeng M; Wang Y; Li C; Li J; Liu H; Zhou Y; Wang J
J Med Chem; 2021 Oct; 64(19):14647-14663. PubMed ID: 34477384
[TBL] [Abstract][Full Text] [Related]
13. Apoptosis targeted therapies in acute myeloid leukemia: an update.
Ball S; Borthakur G
Expert Rev Hematol; 2020 Dec; 13(12):1373-1386. PubMed ID: 33205684
[No Abstract] [Full Text] [Related]
14. Icariside II induces apoptosis in U937 acute myeloid leukemia cells: role of inactivation of STAT3-related signaling.
Kang SH; Jeong SJ; Kim SH; Kim JH; Jung JH; Koh W; Kim JH; Kim DK; Chen CY; Kim SH
PLoS One; 2012; 7(4):e28706. PubMed ID: 22493659
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel glycogen synthase kinase-3α inhibitors: Structure-based virtual screening, preliminary SAR and biological evaluation for treatment of acute myeloid leukemia.
Wang Y; Dou X; Jiang L; Jin H; Zhang L; Zhang L; Liu Z
Eur J Med Chem; 2019 Jun; 171():221-234. PubMed ID: 30925338
[TBL] [Abstract][Full Text] [Related]
16. New tranylcypromine derivatives containing sulfonamide motif as potent LSD1 inhibitors to target acute myeloid leukemia: Design, synthesis and biological evaluation.
Liang L; Wang H; Du Y; Luo B; Meng N; Cen M; Huang P; Ganesan A; Wen S
Bioorg Chem; 2020 Jun; 99():103808. PubMed ID: 32334189
[TBL] [Abstract][Full Text] [Related]
17. Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia.
Zhang Q; Hossain DM; Duttagupta P; Moreira D; Zhao X; Won H; Buettner R; Nechaev S; Majka M; Zhang B; Cai Q; Swiderski P; Kuo YH; Forman S; Marcucci G; Kortylewski M
Blood; 2016 Mar; 127(13):1687-700. PubMed ID: 26796361
[TBL] [Abstract][Full Text] [Related]
18. Blockade of JAK2/STAT3 intensifies the anti-tumor activity of arsenic trioxide in acute myeloid leukemia cells: Novel synergistic mechanism via the mediation of reactive oxygen species.
Mesbahi Y; Zekri A; Ghaffari SH; Tabatabaie PS; Ahmadian S; Ghavamzadeh A
Eur J Pharmacol; 2018 Sep; 834():65-76. PubMed ID: 30012499
[TBL] [Abstract][Full Text] [Related]
19. Discovery of orally active indirubin-3'-oxime derivatives as potent type 1 FLT3 inhibitors for acute myeloid leukemia.
Jeong P; Moon Y; Lee JH; Lee SD; Park J; Lee J; Kim J; Lee HJ; Kim NY; Choi J; Heo JD; Shin JE; Park HW; Kim YG; Han SY; Kim YC
Eur J Med Chem; 2020 Jun; 195():112205. PubMed ID: 32272419
[TBL] [Abstract][Full Text] [Related]
20. Discovery of monocarbonyl curcumin-BTP hybrids as STAT3 inhibitors for drug-sensitive and drug-resistant breast cancer therapy.
Zhang W; Guo J; Li S; Ma T; Xu D; Han C; Liu F; Yu W; Kong L
Sci Rep; 2017 Apr; 7():46352. PubMed ID: 28397855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
